Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients
The first results from the MATRix/IELSG43 trial indicate that standard consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation results in significantly better outcomes when compared to non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen